We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Uncertainty Reigns in Adaptive Trial Design
Uncertainty Reigns in Adaptive Trial Design
December 14, 2006
The FDA, European regulators and industry are struggling to agree on a standard for the amount of data sufficient for sponsors to submit drug applications — a key obstacle to widespread use of adaptive trial designs, sources say.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor